SEC Comment Letter 0000000000-23-003441 to Ambrx Biopharma Inc. (CIK 0001836056)
Ambrx Biopharma Inc. (CIK 0001836056)
Date: April 5, 2023 · CIK: 0001836056 · Accession: 0000000000-23-003441
AI Filing Summary & Sentiment
File numbers found in text: 333-271008
Letter
United States securities and exchange commission logo April 5, 2023 Daniel O'Connor President and Chief Executive Officer Ambrx Biopharma Inc. 10975 North Torrey Pines Road La Jolla, California 92037 Re:Ambrx Biopharma Inc. Registration Statement on Form S-3 Filed March 30, 2023 File No. 333-271008 Dear Daniel O'Connor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Carlos Ramirez, Esq.
Show Raw Text
United States securities and exchange commission logo
April 5, 2023
Daniel O'Connor
President and Chief Executive Officer
Ambrx Biopharma Inc.
10975 North Torrey Pines Road
La Jolla, California 92037
Re:Ambrx Biopharma Inc.
Registration Statement on Form S-3
Filed March 30, 2023
File No. 333-271008
Dear Daniel O'Connor:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Carlos Ramirez, Esq.